OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
IRVINE, Calif., July 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise acquired shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the Food and Drug Administration; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news reached the public, shares of Ocular declined in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
